203 related articles for article (PubMed ID: 29548657)
1. Clinical impact of minocycline on afatinib-related rash in patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations.
Goto A; Ozawa Y; Koda K; Akahori D; Koyauchi T; Amano Y; Kakutani T; Sato Y; Hasegawa H; Matsui T; Yokomura K; Suda T
Respir Investig; 2018 Mar; 56(2):179-183. PubMed ID: 29548657
[TBL] [Abstract][Full Text] [Related]
2. Skin Rash Can Be a Useful Marker for Afatinib Efficacy.
Nasu S; Suzuki H; Shiroyama T; Tanaka A; Iwata K; Ryota N; Ueda Y; Takata SO; Masuhiro K; Morita S; Morishita N; Okamoto N; Hirashima T
Anticancer Res; 2018 Mar; 38(3):1783-1788. PubMed ID: 29491117
[TBL] [Abstract][Full Text] [Related]
3. Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
Kudo K; Hotta K; Bessho A; Nogami N; Kozuki T; Kuyama S; Inoue K; Harita S; Okada T; Gemba K; Fujii M; Takigawa N; Oda N; Tanimoto M; Kiura K
Cancer Chemother Pharmacol; 2016 May; 77(5):1005-9. PubMed ID: 27029623
[TBL] [Abstract][Full Text] [Related]
4. [Retrospective Analysis of the Afatinib Clinical Pathway during the 28-Day Introductory Period-The Japanese Style of Collaborative Drug Therapy Management(J-CDTM)].
Iwata K; Ryota N; Hikita A; Sando M; Suzuki H; Tamiya M; Azuma Y; Tani E; Hamaguchi M; Tanaka A; Shiroyama T; Morishita N; Okamoto N; Futagami S; Hirashima T
Gan To Kagaku Ryoho; 2015 Aug; 42(8):967-72. PubMed ID: 26321711
[TBL] [Abstract][Full Text] [Related]
5. Clinical analysis of patients treated with afatinib for advanced non-small cell lung cancer: A Nagano Lung Cancer Research Group observational study.
Wada Y; Koyama S; Kuraishi H; Miyahara T; Yoshiike F; Agatsuma T; Yamamoto R; Ono Y; Suzuki T; Hachiya T; Gomi D; Tateishi K; Hanaoka M; Koizumi T
Respir Investig; 2016 Nov; 54(6):462-467. PubMed ID: 27886858
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations.
Tanaka H; Taima K; Tanaka Y; Itoga M; Ishioka Y; Nakagawa H; Baba K; Hasegawa Y; Takanashi S; Tasaka S
Med Oncol; 2018 Feb; 35(3):34. PubMed ID: 29423683
[TBL] [Abstract][Full Text] [Related]
7. Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.
Melosky B; Anderson H; Burkes RL; Chu Q; Hao D; Ho V; Ho C; Lam W; Lee CW; Leighl NB; Murray N; Sun S; Winston R; Laskin JJ
J Clin Oncol; 2016 Mar; 34(8):810-5. PubMed ID: 26573073
[TBL] [Abstract][Full Text] [Related]
8. A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
Moran T; Palmero R; Provencio M; Insa A; Majem M; Reguart N; Bosch-Barrera J; Isla D; Costa EC; Lee C; Puig M; Kraemer S; Schnell D; Rosell R
Lung Cancer; 2017 Jun; 108():154-160. PubMed ID: 28625629
[TBL] [Abstract][Full Text] [Related]
9. Tolerability and efficacy of afatinib at a low starting dosage in 10 elderly or low performance status patients with advanced refractory non-small-cell lung cancer.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Respir Investig; 2016 Nov; 54(6):468-472. PubMed ID: 27886859
[TBL] [Abstract][Full Text] [Related]
10. Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting.
Khrystolubova N; Shieh M; Patel AJ; Bailey R
J Oncol Pharm Pract; 2020 Jan; 26(1):13-22. PubMed ID: 30832554
[TBL] [Abstract][Full Text] [Related]
11. Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer.
Lee Y; Lee KH; Lee GK; Lee SH; Lim KY; Joo J; Go YJ; Lee JS; Han JY
Cancer Res Treat; 2017 Oct; 49(4):1001-1011. PubMed ID: 28111428
[TBL] [Abstract][Full Text] [Related]
12. Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib.
Cheema PK; Thawer A; Leake J; Cheng SY; Khanna S; Charles Victor J
Support Care Cancer; 2019 Mar; 27(3):1029-1039. PubMed ID: 30116943
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
Murakami H; Tamura T; Takahashi T; Nokihara H; Naito T; Nakamura Y; Nishio K; Seki Y; Sarashina A; Shahidi M; Yamamoto N
Cancer Chemother Pharmacol; 2012 Apr; 69(4):891-9. PubMed ID: 22071596
[TBL] [Abstract][Full Text] [Related]
14. Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer.
Fujiwara Y; Kiura K; Toyooka S; Takigawa N; Tokumo M; Hotta K; Aoe M; Tabata M; Matsuo K; Date H; Tanimoto M
Lung Cancer; 2006 Apr; 52(1):99-103. PubMed ID: 16503086
[TBL] [Abstract][Full Text] [Related]
15. A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 1401).
Okajima M; Miura S; Watanabe S; Tanaka H; Ito K; Ishida T; Makino M; Iwashima A; Matsumoto N; Sato K; Ichikawa K; Abe T; Yoshizawa H; Kikuchi T
Transl Lung Cancer Res; 2021 Jan; 10(1):252-260. PubMed ID: 33569309
[TBL] [Abstract][Full Text] [Related]
16. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Takeda M; Okamoto I; Nakagawa K
Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
[TBL] [Abstract][Full Text] [Related]
17. Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients.
Arrieta O; Vega-González MT; López-Macías D; Martínez-Hernández JN; Bacon-Fonseca L; Macedo-Pérez EO; Ramírez-Tirado LA; Flores-Estrada D; de la Garza-Salazar J
Lung Cancer; 2015 Jun; 88(3):282-8. PubMed ID: 25882778
[TBL] [Abstract][Full Text] [Related]
18. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
[TBL] [Abstract][Full Text] [Related]
19. Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancer.
Ichiki M; Wataya H; Yamada K; Tsuruta N; Takeoka H; Okayama Y; Sasaki J; Hoshino T
Onco Targets Ther; 2017; 10():5107-5113. PubMed ID: 29123409
[TBL] [Abstract][Full Text] [Related]
20. Metabolic complete tumor response in a patient with
Puliafito I; Esposito F; Raciti G; Giuffrida P; Caltavuturo C; Colarossi C; Munao S; Sciacca D; Giuffrida D
J Int Med Res; 2022 Mar; 50(3):3000605211058864. PubMed ID: 35291829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
